Alys Pharmaceuticals launched in February 2024 with $100m seed financing from health care-focused investment firm Medicxi and the backing of world-leading experts in the field. Francesco De Rubertis, chair of Alys and a partner at Medicxi, and chief operating officer Thibaud Portal explained to In Vivo the rationale behind merging six companies to create an ambitious immuno-dermatology group.
Alys combines the assets of three US-based start-ups (Aldena Therapeutics, Klirna Biotech and Nira Biosciences) and three headquartered in the...